Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Council to Collect Data from 200,000 Diabetic Nephropathy Patients
November 17, 2008
- 15 Doctors Certified as First Pharmaceutical Physicians
November 17, 2008
- Operating Profits of Top-Eight Domestic Companies Down Due to Aggressive Investments
November 17, 2008
- Sales of Irbesartan Total \2.3 Bil. in First 3 Months
November 17, 2008
- Price Settlement Rate Exceeds the Target of 70%
November 17, 2008
- 99 Generics Included in Nov. NHI Price Listing
November 17, 2008
- Kyowa Kirin to Focus on Both Small Molecules, Antibodies
November 17, 2008
- Merck Serono to Accelerate Domestic Development to Achieve US$500 Mil. Sales
November 17, 2008
- Bikaken, Lilly TB Drug Discovery Initiative to Jointly Develop CPZEN-45 for XDR-TB
November 17, 2008
- Early Treatment of COPD Essential: UPLIFT Study on Spiriva
November 17, 2008
- 46th JSCO Annual Meeting
November 17, 2008
- Delay in NDA Review by FDA Disappoints Industry: Mr Hasegawa
November 17, 2008
- TOPICS／2008 JCA-Mauvernay Award Granted to Profs. H. Ichijo and H. Mano
November 17, 2008
- Astellas: R&D Costs Depress Operating Profits 11%
November 17, 2008
- Sanofi-aventis Enhances Its R&D Presence in China
November 17, 2008
- MTPC to Beef Up Domestic Marketing Force
November 17, 2008
- MOF Council Concerned about Little Progress in Use of Generics
November 17, 2008
- Effects of Amlodipine Generics within DSP's Expectations
November 17, 2008
- REGULATORY NEWS IN BRIEF
November 17, 2008
- Kyowa Hakko Kirin: Addition of Kirin Pharma Boosts Sales, Profits
November 10, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…